Analogue-Based Drug Discovery II

Copyright © 2010 Wiley-VCH Verlag GmbH & Co. KGaA

Analogue-Based Drug Discovery II

Editor(s): János Fischer, C. Robin Ganellin

Published Online: 30 AUG 2010 03:17AM EST

Print ISBN: 9783527325498

Online ISBN: 9783527630035

DOI: 10.1002/9783527630035

About this Book

Product Information

About The Product

Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.
Of interest to virtually every researcher working in drug discovery and pharmaceutical chemistry.

Table of contents

    1. You have free access to this content
      Front Matter (pages I–XXVI)

  2. Part I: General Aspects

    1. Chapter 1

      Optimizing Drug Therapy by Analogues (pages 1–28)

      Prof., Dr. János Fischer, Prof., Dr. C. Robin Ganellin, John Proudfoot and Erika M. Alapi

    2. You have free access to this content

      Chapter 2

      Standalone Drugs (pages 29–59)

      Prof. Dr. János Fischer, Prof. Dr. C. Robin Ganellin, Arun Ganesan and John Proudfoot

    3. Chapter 3

      Application of Molecular Modeling in Analogue-Based Drug Discovery (pages 61–82)

      György G. Ferenczy

    4. Chapter 4

      Issues for the Patenting of Analogues (pages 83–106)

      Stephen C. Smith

  3. Part II: Analogue Classes

    1. Chapter 5

      Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes (pages 107–134)

      Jens-Uwe Peters and Patrizio Mattei

    2. Chapter 6

      Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction (pages 135–172)

      Nils Griebenow, Helmut Haning and Erwin Bischoff

    3. Chapter 7

      Rifamycins, Antibacterial Antibiotics and Their New Applications (pages 173–187)

      Enrico Selva and Giancarlo Lancini

    4. Chapter 8

      Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs (pages 189–215)

      András Nemes

    5. Chapter 9

      Anthracyclines, Optimizing Anticancer Analogues (pages 217–241)

      Federico-Maria Arcamone

    6. Chapter 10

      Paclitaxel and Epothilone Analogues, Anticancer Drugs (pages 243–267)

      Paul W. Erhardt and Mohammad El-Dakdouki

    7. Chapter 11

      Selective Serotonin Reuptake Inhibitors for the Treatment of Depression (pages 269–295)

      Wayne E. Childers and David P. Rotella

    8. Chapter 12

      Muscarinic Receptor Antagonists in the Treatment of COPD (pages 297–318)

      Matthias Grauert, Michael P. Pieper and Paola Casarosa

    9. Chapter 13

      β-Adrenoceptor Agonists and Asthma (pages 319–331)

      Giovanni Gaviraghi

  4. Part III: Case Histories

    1. Chapter 14

      Liraglutide, a GLP-1 Analogue to Treat Diabetes (pages 333–357)

      Lotte B. Knudsen

    2. Chapter 15

      Eplerenone: Selective Aldosterone Antagonist (pages 359–381)

      Jaroslav Kalvoda and Marc de Gasparo

    3. Chapter 16

      Clevudine, to Treat Hepatitis B Viral Infection (pages 383–408)

      Ashoke Sharon, Ashok K. Jha and Professor Chung K. Chu

    4. Chapter 17

      Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 (pages 409–441)

      Jerome Guillemont, Luc Geeraert, Jan Heeres and Paul J. Lewi

    5. Chapter 18

      Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-Drug Resistant HIV (pages 443–463)

      Suvit Thaisrivongs, Joseph W. Strohbach and Steve R. Turner

    6. Chapter 19

      Lapatinib, an Anticancer Kinase Inhibitor (pages 465–492)

      Karen Lackey

    7. Chapter 20

      Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia (pages 493–506)

      Jagabandhu Das and Joel C. Barrish

    8. Chapter 21

      Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder (pages 507–524)

      Magid Abou-Gharbia and Wayne E. Childers

    1. You have free access to this content
      Index (pages 525–538)

SEARCH